Trypanosomiasis, African Clinical Trial
— OXA002Official title:
Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study
Verified date | January 2022 |
Source | Drugs for Neglected Diseases |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to assess efficacy and safety of Acoziborole (SCYX-7158) given as a single dose oral treatment for adult patients (above or equal 15) in the fasting state with T.b. Gambiense HAT
Status | Completed |
Enrollment | 260 |
Est. completion date | August 28, 2020 |
Est. primary completion date | August 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: - Male or female patient - 15 years of age or older - Signed informed consent form (as well as assent from illiterate and under-age patients, and those unable to give consent) - Karnofsky Performance Status above 50 - Able to ingest oral tablets - Having a permanent address or being traceable by other persons - Able to comply with the schedule of follow-up visits and requirements of the study - Agreement to be hospitalised in order to receive treatment - For patients with late-stage HAT: - Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph and/or the CSF, at the investigational centre - If trypanosomes are found in the blood or lymph, but not in the CSF, the CSF WBC, measured at the investigational centre, must be above 20/µL for the patient to be included in the cohort of patients with late-stage HAT - For patients with early- or intermediate-stage HAT: - Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph, at the investigational centre - Absence of parasites in the CSF - The CSF WBC, measured at the investigational centre, must be between 6 and 20/µL for the patient to be included in the cohort of patients with intermediate-stage HAT and equal to or below 5/µL for the patient to be included in the cohort of patients with early-stage HAT. Exclusion Criteria: - Severe malnourishment, defined as body-mass index (BMI) below 16 - Pregnancy or breastfeeding (for women of child-bearing potential, confirmed pregnancy on a urine pregnancy test performed within 24 hours prior to administration of SCYX-7158) - Clinically significant medical condition that could, in the opinion of the Investigator, jeopardise the patient's safety or interfere with participation in the study, including, but not limited to significant liver or cardiovascular disease, suspected or proven active infection, central nervous system trauma or seizure disorder, coma or consciousness disturbances - Severely deteriorated health status, e.g. due to cardiovascular shock, respiratory distress syndrome or end-stage disease - Previously treated for HAT (except prior treatment with pentamidine) - Prior enrolment in the study - Foreseeable difficulty complying with follow-up, including migrant worker, refugee status, itinerant trader etc. - Current alcohol abuse or drug addiction - Not tested for malaria and/or not having received appropriate treatment for malaria - Not having received appropriate treatment for soil-transmitted helminthiasis - Clinically significant abnormal laboratory values including Aspartate AminoTransferase(AST) and/or AlanineAminoTransferase (ALT) more than 2 times the upper limit of normal (ULN), total bilirubin more than 1.5 ULN, severe leukopenia at less than 2000/mm3, Potassium below 3.5 mmol/L, any other clinically significant abnormal laboratory value |
Country | Name | City | State |
---|---|---|---|
Congo, The Democratic Republic of the | Hopital General de réference de Bagata | Bagata | Kwilu |
Congo, The Democratic Republic of the | Hopital Général de réference de Bandundu | Bandundu | |
Congo, The Democratic Republic of the | Hôpital Général de Référence de NGandajika | Gandajika | Kasai Oriental |
Congo, The Democratic Republic of the | Hôpital de référence d'Isangi | Isangi | |
Congo, The Democratic Republic of the | Hôpital secondaire de Katanda | Katanda | Kasaï-Oriental |
Congo, The Democratic Republic of the | Centre de Traitement de Kimpese | Kimpese | Bas Congo |
Congo, The Democratic Republic of the | Hôpital Général de Référence Roi Baudouin | Kinshasa | |
Congo, The Democratic Republic of the | Hôpital Généal de référence de Kwamouth | Kwamouth | Mai-Ndombe |
Congo, The Democratic Republic of the | Hôpital Général de référence de Masi-Manimba | Masi-Manimba | Kwilu |
Congo, The Democratic Republic of the | Hôpital de Dipumba | Mbuji-Mayi | Kasai-Oriental |
Congo, The Democratic Republic of the | Centre de Traitement de NKara | Nkara | Bandundu |
Guinea | Centre de Traitement de la THA de Dubreka | Dubréka | Dubreka |
Lead Sponsor | Collaborator |
---|---|
Drugs for Neglected Diseases |
Congo, The Democratic Republic of the, Guinea,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Success or failure for patients in late stage HAT | Success is defined as a cure, according to the criteria adapted from the World Health Organization(WHO) | 18 months follow up | |
Secondary | Success or failure for all stage HAT patients | Success is defined as a cure, according to the criteria adapted from the WHO | 6, 12 and 18 months follow up | |
Secondary | Time to Failure in Patients with Late-stage HAT | Time of the first objective evidence of failure. | 18 months follow up | |
Secondary | Occurence of adverse events | Occurrence of any Adverse Event, including an abnormal laboratory test result, during the observation period and until 6 month follow-up. | From day 1 until 6 months follow-up | |
Secondary | Occurence of serious advers events | Occurrence of any serious adverse events during the observation period and until 18 month follow-up | Between the day 1 and the end of the follow-up period (18 month) | |
Secondary | Pharmacokinetics measure | SCYX-7158 Area Under Curve in whole blood and in the Cerebrospinal fluid (CSF); | Days 1, 2, 3, 4, 5, 11, Month 3 and Month 6 follow up visits | |
Secondary | Pharmacokinetics measure | SCYX-7158 concentration in whole blood and in the Cerebrospinal fluid; | Days 1, 2, 3, 4, 5, 11, Month 3 and Month 6 follow up visits | |
Secondary | Electrocardiogram measure | PR interval | Days 1, 2, 3, 4, 5 and 11 | |
Secondary | Electrocardiogram measure | quantitative description of PR interval | Days 1, 2, 3, 4, 5 and 11 | |
Secondary | Electrocardiogram measure | quantitative description of RR interval | Days 1, 2, 3, 4, 5 and 11 | |
Secondary | Electrocardiogram measure | quantitative description of QRs interval | Days 1, 2, 3, 4, 5 and 11 | |
Secondary | Electrocardiogram measure | quantitative description of QTcF interval | Days 1, 2, 3, 4, 5 and 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01483170 -
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
|
Phase 1 | |
Terminated |
NCT00489658 -
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
|
Phase 2/Phase 3 | |
Completed |
NCT03025789 -
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
|
Phase 3 | |
Completed |
NCT02571062 -
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
|
Phase 1 | |
Terminated |
NCT00330148 -
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
|
Phase 3 | |
Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05645822 -
Screen and Treat Implementation for HAT Control
|
||
Completed |
NCT05947604 -
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
|
Phase 1 | |
Completed |
NCT01533961 -
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
|
Phase 1 | |
Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT00802594 -
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
|
Phase 2 | |
Completed |
NCT00146627 -
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
|
Phase 3 |